Nanobots heading to eye delivery
German researchers have developed a drug delivery nanobot that can propel through the eye.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Argenx antibody kills AML
/in News/by Thomas GabrielczykArgenx SE announced it achieved an overall response rate of 92% in patients with AML with its anti-TNFSF7 (CD70) antibody cusatuzumab.
Sanofi and Denali Therapeutics ink 1.125bn deal in neurology/inflammation
/in News/by Thomas GabrielczykSanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics.
ProQR in licence deal with Ionis Pharmaceuticals
/in News/by Thomas GabrielczykDutch ProQR NV has licensed global commercialisation rights to IONIS-RHO-2.5Rx (QR-1123) from Ionis Pharmaceuticals, to treat autosomal dominant retinitis pigmentosa (adRP)
Newron bags 40m EIB loan
/in News/by Thomas GabrielczykThe EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to 40m to support the development of the company’s late-stage pipeline.
TES Pharma presents new treatment approach towards AKI and NALFD
/in News/by Thomas GabrielczykTES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature.
MEPs vote for ban of single-use plastics
/in News/by Thomas GabrielczykThe European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021.
AstraZeneca and Innate Pharma in US$5bn oncology deal
/in News/by Thomas GabrielczykAstraZeneca plc has extended its immunoncology pipeline by an extension of its partnership with French Innate Pharma SA.
Takeda strikes US$640m deal with Enterome
/in News/by Thomas GabrielczykFrench Enterome SA has added a second licence agreement with Takeda to its deal portfolio, projecting possible payments of US$640m.
EMA recommends four biologicals for market
/in News/by Thomas GabrielczykThe European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU.